RxDoctor Payments Data

Belinda Bagby

Psychiatric/Mental Health · Hutchinson, KSNPI 1083042956

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $34,100 of the $38,556 with a category attached, or 88.4%. AbbVie accounts for 95.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $18,142 and has fallen 87.1% since, to $2,340 in 2025. Among psychiatric/mental health clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$38,556in general payments, 2019–2025

Across 136 payments — averaging $283.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$37K
  • Neurocrine Biosciences, Inc.$244
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$233
  • Abbott$217
  • Supernus Pharmaceuticals, Inc.$206
  • Axsome Therapeutics, Inc.$160
  • plus $680 from 12 others

What the payments were for

  • Speaking & faculty fees$34,10088%
  • Travel & lodging$2,0585%
  • Food & beverage$2,3056%
  • Education$940%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,556 in reported general payments places this provider in the 95th percentile of 404 psychiatric/mental health providers in Kansas.

See all psychiatric/mental health providers in Kansas

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine58$413,425
VraylarCariprazine Hcl200$301,655
Lurasidone Hcl42$23,291
BelsomraSuvorexant40$20,034
RexultiBrexpiprazole12$16,946
Aripiprazole168$13,578
QelbreeViloxazine Hcl15$13,416
Desvenlafaxine Succinate ErDesvenlafaxine Succinate251$12,573
QuviviqDaridorexant Hcl17$10,982
TrintellixVortioxetine Hydrobromide18$8,964
Hydroxyzine Hcl213$5,595
Quetiapine Fumarate239$5,008
Atomoxetine Hcl28$4,026
Paliperidone ErPaliperidone19$2,846
Duloxetine Hcl183$2,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$57$413,42558 claims
AbbVieVraylar$36,815$301,655200 claims
Supernus Pharmaceuticals, Inc.Qelbree$206$13,41615 claims
Idorsia Pharmaceuticals US IncQuviviq$29$10,98217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 404 psychiatric/mental health providers in Kansas.

Other psychiatric/mental health in Hutchinson

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →